OFATUMUMAB FOR TREATING PEDIATRIC MS

OFATUMUMAB FOR TREATING PEDIATRIC MS

The invention concerns ofatumumab for use in the treatment or prevention of pediatric multiple sclerosis (MS). According to the invention, ofatumumab is administered during a loading dose regimen at weeks 0, 1, 2 of the dosage regimen; and ofatumumab is administered during a maintenance dose regimen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: BAGGER, Morten, SU, Wendy, HÄRING, Dieter Adrian, GRAHAM, Gordon, MERSCHHEMKE, Martin
Format: Patent
Sprache:eng
Schlagworte:
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator BAGGER, Morten
SU, Wendy
HÄRING, Dieter Adrian
GRAHAM, Gordon
MERSCHHEMKE, Martin
description The invention concerns ofatumumab for use in the treatment or prevention of pediatric multiple sclerosis (MS). According to the invention, ofatumumab is administered during a loading dose regimen at weeks 0, 1, 2 of the dosage regimen; and ofatumumab is administered during a maintenance dose regimen starting at week eight of the dosage regimen and continuing thereafter every six weeks.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US2024343821A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US2024343821A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US2024343821A13</originalsourceid><addsrcrecordid>eNrjZFDxd3MMCfUN9XV0UnDzD1IICXJ1DPH0c1cIcHXxdAwJ8nRW8A3mYWBNS8wpTuWF0twMym6uIc4euqkF-fGpxQWJyal5qSXxocFGBkYmxibGFkaGjobGxKkCAAkGI-Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>OFATUMUMAB FOR TREATING PEDIATRIC MS</title><source>esp@cenet</source><creator>BAGGER, Morten ; SU, Wendy ; HÄRING, Dieter Adrian ; GRAHAM, Gordon ; MERSCHHEMKE, Martin</creator><creatorcontrib>BAGGER, Morten ; SU, Wendy ; HÄRING, Dieter Adrian ; GRAHAM, Gordon ; MERSCHHEMKE, Martin</creatorcontrib><description>The invention concerns ofatumumab for use in the treatment or prevention of pediatric multiple sclerosis (MS). According to the invention, ofatumumab is administered during a loading dose regimen at weeks 0, 1, 2 of the dosage regimen; and ofatumumab is administered during a maintenance dose regimen starting at week eight of the dosage regimen and continuing thereafter every six weeks.</description><language>eng</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20241017&amp;DB=EPODOC&amp;CC=US&amp;NR=2024343821A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20241017&amp;DB=EPODOC&amp;CC=US&amp;NR=2024343821A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>BAGGER, Morten</creatorcontrib><creatorcontrib>SU, Wendy</creatorcontrib><creatorcontrib>HÄRING, Dieter Adrian</creatorcontrib><creatorcontrib>GRAHAM, Gordon</creatorcontrib><creatorcontrib>MERSCHHEMKE, Martin</creatorcontrib><title>OFATUMUMAB FOR TREATING PEDIATRIC MS</title><description>The invention concerns ofatumumab for use in the treatment or prevention of pediatric multiple sclerosis (MS). According to the invention, ofatumumab is administered during a loading dose regimen at weeks 0, 1, 2 of the dosage regimen; and ofatumumab is administered during a maintenance dose regimen starting at week eight of the dosage regimen and continuing thereafter every six weeks.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZFDxd3MMCfUN9XV0UnDzD1IICXJ1DPH0c1cIcHXxdAwJ8nRW8A3mYWBNS8wpTuWF0twMym6uIc4euqkF-fGpxQWJyal5qSXxocFGBkYmxibGFkaGjobGxKkCAAkGI-Q</recordid><startdate>20241017</startdate><enddate>20241017</enddate><creator>BAGGER, Morten</creator><creator>SU, Wendy</creator><creator>HÄRING, Dieter Adrian</creator><creator>GRAHAM, Gordon</creator><creator>MERSCHHEMKE, Martin</creator><scope>EVB</scope></search><sort><creationdate>20241017</creationdate><title>OFATUMUMAB FOR TREATING PEDIATRIC MS</title><author>BAGGER, Morten ; SU, Wendy ; HÄRING, Dieter Adrian ; GRAHAM, Gordon ; MERSCHHEMKE, Martin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US2024343821A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2024</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>BAGGER, Morten</creatorcontrib><creatorcontrib>SU, Wendy</creatorcontrib><creatorcontrib>HÄRING, Dieter Adrian</creatorcontrib><creatorcontrib>GRAHAM, Gordon</creatorcontrib><creatorcontrib>MERSCHHEMKE, Martin</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>BAGGER, Morten</au><au>SU, Wendy</au><au>HÄRING, Dieter Adrian</au><au>GRAHAM, Gordon</au><au>MERSCHHEMKE, Martin</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>OFATUMUMAB FOR TREATING PEDIATRIC MS</title><date>2024-10-17</date><risdate>2024</risdate><abstract>The invention concerns ofatumumab for use in the treatment or prevention of pediatric multiple sclerosis (MS). According to the invention, ofatumumab is administered during a loading dose regimen at weeks 0, 1, 2 of the dosage regimen; and ofatumumab is administered during a maintenance dose regimen starting at week eight of the dosage regimen and continuing thereafter every six weeks.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_US2024343821A1
source esp@cenet
subjects CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
title OFATUMUMAB FOR TREATING PEDIATRIC MS
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T17%3A44%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=BAGGER,%20Morten&rft.date=2024-10-17&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS2024343821A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true